Vertex Pharmaceuticals (NASDAQ: VRTX) has built a cystic fibrosis (CF) treatment empire that brings in billions of dollars in earnings annually. And just recently, the company demonstrated it could successfully expand beyond this specialty when it won approval for a gene-editing treatment for blood disorders. Casgevy, for beta thalassemia and sickle cell disease, may become another source of billion-dollar revenue for Vertex and partner CRISPR Therapeutics.

Investors have rewarded the biotech giant by piling into the shares, helping them rise to a record high. Over the past year, Vertex stock has climbed almost 50%. Now you may be wondering if, after those gains, it's too late to get in on this exciting biotech story. Well, I've got good news for you: It isn't. In fact, there are three reasons to load up on Vertex shares right now.

Image source: Getty Images.

Continue reading

Source Fool.com